Amy Ritter, PhD

Ben Venue Laboratories announced that it has voluntarily entered into a consent decree with FDA over violations of cGMP.

According to the Federal Trade Commission, the number of potentially anticompetitive patent dispute settlements between branded and generic drug companies increased between 2011 and 2012.

Lonza will invest CHF 14 million ($15.1 million) to double the existing large-scale manufacturing capacity in Visp, Switzerland.

AbbVie, a research-focused, specialty biopharmaceutical company that was spun off from Abbott Pharmaceuticals, was officially launched on Jan. 2, 2013.

Amgen has agreed to pay $762 million to resolve criminal liability and false claims act allegations.

Anthrax antitoxin is the first monoclonal antibody approved under FDA's Animal Efficacy Rule, and the first product from BARDA's Project Bioshield to receive FDA approval.

Pfizer has agreed to pay $55 million plus interest to settle charges that Wyeth (acquired by Pfizer in October, 2009) improperly promoted the drug Protonix (pantoprazole).

Biogen Idec and Isis Pharmaceuticals announced that they have entered into a global collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders.

Eli Lilly released its annual report containing updates on progress and new initiatives in corporate responsibility.

Recent research examines the sequence of events underlying cellular reprogramming, which may aid in better control of the production of induced pluripotent stem cells.